Serious complications of pancreatoduodenectomy correlate with lower rates of adjuvant chemotherapy: Would high-risk patients benefit from neoadjuvant therapy?

Abstract

Patients who suffer a serious complication of pancreatoduodenectomy (PD) may have their adjuvant chemotherapy (AC) delayed or omitted as a result. We aimed to investigate whether PD complications affected AC rates. A retrospective analysis of all PD patients with histologically-confirmed pancreatic ductal adenocarcinoma (2006-2015) was performed; 90-day mortality patients were excluded. Patients who commenced AC were compared to those who did not (morbidity rates and survival) and patients who developed selected postoperative complications were compared to those who did not (AC rates and survival). 157 patients were included and 90-day mortality was 3.8%. Of the remaining patients, 102 (68.5%) received AC (AC data unavailable for two patients). Survival was longer in the AC group (p=0.004). AC patients had less frequently experienced a postoperative chest infection (8.82% vs 34.0%, p=0.0003) or a postoperative complication which was Clavien-Dindo (CD) grade≥II (29.4% vs 57.4%, p=0.0019) or≥III (6.86% vs 21.3%, p=0.023). Patients who experienced a postoperative chest infection (36.0% vs 75.0%, p=0.0003) or a postoperative complication which was CD grade≥II (48.9% vs 73.1%, p=0.0099) or≥III (29.4% vs 70.3%, p=0.0018) less frequently commenced AC. Patients who received AC had less frequently experienced a serious postoperative complication. Efforts should be made to preoperatively identify those who are high-risk for a serious complication as this cohort may benefit from neoadjuvant therapy.